Business Wire

Quantori Strengthens Global Leadership Team, Names Senior Business Leader Solman Rahman as Executive Vice President, Europe

8.9.2021 07:00:00 EEST | Business Wire | Press release

Share

Quantori, a leading global provider of end-to-end software engineering, scientific informatics, data sciences and digital transformation services for life science and healthcare companies, today announced the appointment of Solman Rahman to Executive Vice President, Europe to support Quantori’s aggressive growth strategy and strengthen its market position as a premier global services provider.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005840/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Solman Rahman, Executive Vice President, Europe, Quantori (Photo: Business Wire)

“Solman’s wealth of experience in building and scaling business operations for leading technology consulting and digital platform engineering companies serving the European life science and healthcare markets makes him uniquely positioned to lead Quantori’s expansion in this key region,” said Richard Golob, CEO, Quantori. “Europe continues to be a powerhouse of world-class life science and biopharma industry innovation. We look forward to working with Solman in developing strategic client relationships to help biopharma and life science companies deliver critical technology programs and data management imperatives to accelerate development of novel therapeutics."

As Quantori’s Executive Vice President for Europe, Solman will be responsible for developing key partnerships within the EU region’s ecosystem of pharma and healthcare companies, in addition to ensuring delivery of superior services and providing leading technology capabilities to Quantori’s clients. Solman joins Quantori from EPAM Systems where he led the Northern Europe business and where he previously worked with Quantori leadership, including Richard Golob, who led EPAM’s Global Life Sciences Business into the fastest growing unit at EPAM, in addition to Dr. Yuriy Gankin, Quantori’s Chief Scientific Officer, and Vitaliy Aronov, Quantori’s Chief Technology Officer.

“I am thrilled to be rejoining such a brilliant executive team at a very exciting time in Quantori’s growth and development, especially as the European biopharma industry is scaling the use of digital technologies to enable the provision of precision medicines and personalized healthcare,” said Solman. “A major challenge in working with IT outsourcing companies is that they have a limited understanding of the life sciences and healthcare industries. One of Quantori’s key differentiators is its extensive domain knowledge underpinned by true scientific depth. This unique combination enables us to add considerable value from the outset and speed-to-market horsepower to the critical focus of today’s biopharma companies – to accelerate the translation of their research and data insights into a pipeline of new medicines.”

Prior to leading EPAM’s Northern European business, Solman worked at Cognizant in several roles, including serving as Head of Strategic Engagements and Industry Practice leadership. Solman began his career as an analyst at Cowen Inc. in the Technology Investment Banking Group, undertaking equity research in the biopharma and high-tech sectors. He currently serves as a board advisor to Conversationly, a digital agency leveraging messaging, automation and AI technologies to promote conversational commerce. He holds MSc and BSc degrees in Economics & Management and Econometrics from the London School of Economics and Political Science.

“We are thrilled to welcome Solman onboard, and he will be instrumental in our efforts to expand operations in Europe to help biopharma leaders bring novel and life-saving therapies to market through the powerful partnership of digital IT and R&D informatics,” said Yuriy Gankin, PhD, Quantori’s Chief Scientific and Strategy Officer.

About Quantori
Quantori is transforming life sciences and healthcare through the power of digital IT. Quantori develops end-to-end software engineering, scientific informatics, and data science solutions that help biopharma companies accelerate every stage of drug discovery and development. Quantori combines data engineering and advanced analytics with deep scientific domain knowledge to enable life science and healthcare organizations to achieve their digital transformations with greater speed and agility. Learn more about Quantori at www.quantori.com and connect on social media @Twitter, @LinkedIn, and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heidi Creighton
heidi.creighton@quantori.com
Mobile/Text: 978-302-1198

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 16:00:00 EEST | Press release

Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in

Gurobi Launches Intelligence Hub to Deliver AI-Guided Workflows Across the Optimization Lifecycle7.7.2026 16:00:00 EEST | Press release

Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of the Gurobi Intelligence Hub, the new home for Gurobi’s AI-powered optimization agents. The Intelligence Hub is designed to help users build, understand, troubleshoot, and interact with optimization models more effectively. Together, the Hub’s specialized agents leverage generative AI to guide users through workflows across the optimization lifecycle, creating new opportunities to make optimization more accessible, intuitive, and valuable for a broader range of users. The Modeler combines guided workflows with Gurobi’s optimization expertise to help users move from business problem to production-quality optimization model. Through an iterative process that helps refine requirements, validate assumptions, and develop acceptance tests, the Modeler gives users confidence that their model accurately reflects the intended business problem.The Explainer helps users interpret model instances

SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 16:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactions. Having already enabled the issuance and distribution of tokenized funds, SS&C is now extending its innovation roadmap to support the next stage of the digital i

Quaise Energy Raises $134 Million in Initial Close of Series B to Build World’s First Superhot Geothermal Power Plant7.7.2026 15:01:00 EEST | Press release

Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the first close of its Series B financing, raising $134 million with additional equity and debt capital expected to close imminently. The round was led by Prelude Ventures, with strategic investments from JERA and Idemitsu, two of Japan's largest energy companies. Nearly all existing investors, including Safar Partners, participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707844187/en/ The proceeds from Series B will fund Project Obsidian, the world’s first commercial superhot geothermal power plant, and the continued development and commercialization of Quaise's millimeter wave drilling system towards depths in excess of 5 km. Project-level equity and debt financing is concurrently being raised as the company advances toward first revenues secured by yet-undisclosed commercial off-take partners. The Series

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 15:00:00 EEST | Press release

Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye